Elizabeth Bortolon

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Yong S. Chang, Jalila Adnane, Pamela A. Trail et al. · Cancer Chemotherapy and Pharmacology · 2006 · 465 citations

Medicine, Oncology, Pharmacology +16

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

Jennifer Cantley, Xiaofen Ye, Emma Rousseau et al. · Nature Communications · 2022 · 129 citations · Full text

Pharmacy, Molecular Biology, Oncology +14

PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

Michael Berlin, Jennifer Cantley, Mark Bookbinder et al. · Journal of Medicinal Chemistry · 2024 · 30 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +6

Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006)

Joan Levy, Nicole Pauloski, Déborah Braun et al. · Cancer Research · 2006 · 27 citations

Medicine, Oncology, Pharmacology +17